^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

STC-1010

i
Other names: STC-1010
Associations
Trials
Company:
Brenus Pharma
Drug class:
Immunostimulant
Related drugs:
Associations
Trials
over1year
Inovative in vivo (in ovo) CAM model to predict efficacy and mode of action of a new antitumor vaccine stc-1010 on human colorectal adenocarcinoma (AACR 2023)
This in ovo study confirms efficacy of the STC-1010 observed in previous CRC syngeneic models and gives more insight about STC mechanism of action with the activation and maturation of dendritic cells, induction of CD8+ and LTh1 against tumor as the main driver of the response, all without toxicity. Inovotion’s CAM model could be used for indication screening and as a pre-proof-of-concept before syngeneic model study.
Preclinical • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule)
|
IFNG expression
|
STC-1010